---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-23-000160"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:25:59.511030+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q3 net loss $26M; positive V005 trauma trial results, BLA filing planned this quarter

## Summary
- Cash and equivalents $100M; funding from Oberland up to $160M, $40M received.
- Net loss $26.0M Q3 2023 vs $25.3M Q3 2022; R&D expenses $18.6M.
- V005 Phase 2/3 trial: 30-day patency 90.2%, amputation rate 9.8%, infection rate 2.0% (vs historic synthetic benchmarks).
- BLA for HAV in vascular trauma planned for FDA filing in Q4 2023.
- Ukraine humanitarian program: 30-day patency 95%, limb salvage and survival 100%, zero infections.

## SEC filing metadata
- accession: 0001818382-23-000160
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/0001818382-23-000160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/huma-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-23-000160
- JSON: https://secwatch.observer/filing/0001818382-23-000160.json
- Plain text: https://secwatch.observer/filing/0001818382-23-000160.txt

## Key facts
- Earnings Releases
  Humacyte, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000160/0001818382-23-000160-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.